Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases
Open Access
- 17 October 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 165 (1) , 127-137
Abstract
Purpose: To investigate the impact of radiotherapy (RT) and immune checkpoint inhibitor (ICI) sequence on the survival outcome in NSCLC patients with brain metastasis, and decide the best time to initiate RT. Methods: Patients were managed with delayed RT (ICI delivered over 2 weeks prior to RT), concurrent RT (ICI delivered within 2 weeks prior to or after RT), or upfront RT (RT delivered over 2 weeks prior to ICI). Overall survival (OS), intracranial local progression-free survival (iLPFS), and intracranial distant progression-free survival (iDPFS) were assessed. A meta-analysis was performed to analyze the association between survival outcome and RT/ICI sequence. Results: A total of 73 NSCLC patients were identified with a median follow-up of 13.9 months. Patients who receive delayed RT demonstrated shorter iLPFS (P = 0.0029), iDPFS (P = 0.016), and OS (P < 0.001). A meta-analysis was conducted and a total of 4 studies, 254 patients were included. The HR was 0.44 for iDPFS (P = 0.03), 0.41 for OS (P < 0.01) when compared concurrent with delayed RT, 0.21 for iDPFS (P < 0.01), 0.32 for OS (P < 0.01) when compared upfront with delayed RT, consistent with our conclusion that delayed RT brought with worst iDPFS and OS. More importantly, the best overall response rate (BOR) decreased in cases with longer RT and ICI intervals. Patients who receive intervals of RT and ICI within 7 days achieve the best median BOR of − 53%. Conclusions: Delayed RT brought poor survival outcomes including iLPFS, iDPFS, and OS in NSCLC patients. The shorter interval of RT and ICI is associated with better BOR.Keywords
Funding Information
- The National Natural Science Foundation of China (Grant No. 82103498)
- CSCO-Roche research funding (Y-Roche2019/2-0088)
This publication has 41 references indexed in Scilit:
- Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain MetastasesAmerican Journal of Clinical Oncology, 2017
- Response assessment criteria for brain metastases: proposal from the RANO groupThe Lancet Oncology, 2015
- Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined TreatmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature, 2015
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 BlockadeCancer Research, 2014
- Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgeryCancer Medicine, 2014
- Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in miceCancer Immunology, Immunotherapy, 2014
- Ipilimumab and radiation therapy for melanoma brain metastasesCancer Medicine, 2013
- The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapyAnnals of Oncology, 2011
- Phase I/II Study of Ipilimumab for Patients With Metastatic MelanomaJournal of Clinical Oncology, 2008